N@N

Micromet to Present at Two Upcoming Investor Conferences

_{//health-fitness.news-articles.net/content/2011/ .. resent-at-two-upcoming-investor-conferences.html}
^{Published in Health and Fitness on Thursday, February 17th 2011 at 5:25 GMT by Market Wire}  

BETHESDA, Md.--([ BUSINESS WIRE ])--Micromet, Inc. (NASDAQ: MITI), a biopharmaceutical company focused on the development and commercialization of next-generation antibodies for the treatment of cancer, today announced that members of the Companya™s management team will present a corporate overview at two upcoming investor conferences:

2011 RBC Capital MarketsHealthcare Conference
Thursday, March 3, at 1:30 PM ET
New York, NY

ROTH 23rd Annual Growth Stock Conference
Monday, March 14, at 10:30 AM PT
Dana Point, CA

The presentations will be webcast live and may be accessed by visiting the Micromet website at [ www.micromet.com ]. A replay of the webcasts will also be available on the Company's website.

About Micromet, Inc.

Micromet, Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of innovative antibody-based therapies for the treatment of cancer. Its product development pipeline includes novel antibodies generated with its proprietary BiTE® technology, as well as conventional monoclonal antibodies. The Companya™s lead product candidate blinatumomab (MT103) is currently the subject of a European pivotal trial in patients with minimal residual disease positive acute lymphoblastic leukemia. Micromet has collaborations with a number of leading pharmaceutical and biotechnology companies, including Bayer Schering Pharma, Boehringer Ingelheim, MedImmune, Merck Serono, Nycomed and sanofi-aventis. Additional information can be found at [ www.micromet.com ].